Oncoinvent ASA
ONCIN
Rank in Stocks
#24724
Oncoinvent ASA, a clinical-stage firm based in Oslo, Norway, is dedicated to... Oncoinvent ASA, a clinical-stage firm based in Oslo, Norway, is dedicated to developing innovative radiopharmaceutical treatments for various cancers. Its primary therapeutic agent is Radspherin, an alpha-emitting radiotherapeutic, which is currently undergoing investigation in two Phase 1/2a and one randomized Phase 2 clinical trials. This promising candidate is designed to target and treat malignancies that have metastasized to body cavities, specifically including the peritoneum.
Share Price
$6.89
Last synced: 2026-11-09
Market Cap
$30.86M
Change (1 day)
4.16%
Change (1 year)
8.54%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Oncoinvent ASA (ONCIN)
Category
Healthcare
EPS for Oncoinvent ASA (ONCIN)
EPS as of June 2026 TTM: $-9.01
According to Oncoinvent ASA's latest financial reports, its current EPS (TTM) is $-9.01. At the end of 2025 the company had an EPS of $-12.40, a decrease compared to its 2024 EPS of $-0.35.
EPS history for Oncoinvent ASA from 2014 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-9.01 | -27.33% |
| 2025 | $-12.40 | 3,458.26% |
| 2024 | $-0.35 | -73.33% |
| 2023 | $-1.31 | -67.34% |
| 2022 | $-4.00 | -12.55% |
| 2021 | $-4.58 | 0.41% |
| 2020 | $-4.56 | 1.74% |
| 2019 | $-4.48 | -6.06% |
| 2018 | $-4.77 | -13.36% |
| 2017 | $-5.50 | 61.50% |
| 2016 | $-3.41 | 84.23% |
| 2015 | $-1.85 | 5.22% |
| 2014 | $-1.76 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -273.78% |
US
|
|
| $-7.07 | -21.54% |
US
|
|
| $-5.29 | -41.30% |
AU
|
|
| $12.88 | -242.93% |
BE
|
|
| $21.56 | -339.26% |
NL
|
Questions about Oncoinvent ASA's earnings per share (EPS)
What is Oncoinvent ASA's earnings per share (EPS)?
Oncoinvent ASA's earnings per share (EPS) over the last twelve months is $-9.01, as of Jun 2026.
What was Oncoinvent ASA's earnings per share (EPS) in 2025?
In 2025, Oncoinvent ASA's earnings per share (EPS) was $-12.40, compared with $-0.35 in 2024.
How has Oncoinvent ASA's earnings per share (EPS) changed since 2020?
From 2020 to 2025, Oncoinvent ASA's earnings per share (EPS) was highest in 2024 ($-0.35) and lowest in 2025 ($-12.40).
How does Oncoinvent ASA's earnings per share (EPS) compare with similar companies?
Oncoinvent ASA's earnings per share (EPS) ($-9.01) is lower than that of all 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.